Table 1.
Clinical characteristics of the patients reported.
| Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|
| Age, year | 61 | 59 | 73 |
| Gender | Male | Female | Male |
| Pathology | Adenocarcinoma | Adenocarcinoma | Squamous carcinoma |
| Smoking | |||
| Stage | IV (T4N0M1) | IV (T4N0M1) | IV (T3N0M1) |
| Mutation | EGFR L858R | None | EGFR L858R |
| Therapy (response) | |||
| First line | Pemetrexed/cisplatin (PR) | Docetaxel/cisplatin (SD) | Gemcitabine/cisplatin (PR) |
| Second line | Gefitinib (SD) | Pemetrexed/cisplatin (PD) | Icotinib (PD) |
| Third line | Gefitinib | ||
| Forth line | Pemetrexed/carboplatin (SD) | ||
Abbreviations: EGFR, epidermal growth factor receptor; PD, progression disease; PFS, progression-free survival; PR, partial response; SD, stable disease.